Who Gets Access: The Equity Problem in Psychedelic Medicine

“Huxley called the experience 'of inestimable value to everyone.' Oregon sessions cost $300-$2,000 out of pocket. These facts are in tension.”

In The Doors of Perception, Huxley argued that the experience of direct perception was 'of inestimable value to everyone.' The qualitative democracy of the claim is deliberate: not everyone who wants mescaline should have it, but the benefit of opening the reducing valve is not restricted to any class or education level.

The psychedelic therapy market as actually developed is not structurally democratic. In Oregon, a psilocybin session costs between $300 and $2,000 out of pocket, with no insurance coverage as of 2026. Clinical trials require specific diagnoses and geographic proximity. Ketamine infusion clinics cost $400-$800 per session, also typically without insurance.

The MAPS Policy Guidebook (2026) explicitly acknowledges this equity gap, noting the historical invisibility and exploitation of Indigenous people in the American narrative.

The racial equity dimension is sharpest in the cannabis parallel: communities most heavily criminalized under cannabis prohibition have not received commensurate benefit from legalization. Oregon's Measure 109 required an underserved community access program; Colorado's Proposition 122 included equity licensing provisions. Whether these provisions translate into meaningful equitable access or primarily function as symbolic concessions is the open empirical question.

Sources

• Huxley, The Doors of Perception (1954)
• Oregon Health Authority Psilocybin Services (2024)
• MAPS Policy Guidebook (2026)